Sugi Predict

Sugi Predict / Compounds / SCHEMBL4151725

SCHEMBL4151725

SCHEMBL4151725

O=C1NCc2ncncc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MKNK2 Q9HBH9 11/20 0.41
▸ MKNK1 Q9BUB5 3/20 0.40
▸ CDC25B P30305 1/20 0.36
▸ CA12 O43570 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CDC7 O00311 2/20 0.34
▸ PARP16 Q8N5Y8 1/20 0.33
▸ PARP3 Q9Y6F1 1/20 0.33
▸ MAPKAPK2 P49137 1/20 0.32
▸ PIM1 P11309 1/20 0.32
▸ CSNK1A1 P48729 1/20 0.32
▸ CDK5 Q00535 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ CLK4 Q9HAZ1 1/20 0.32
▸ DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30059171 1.00 MKNK2 (0.41) MKNK2MKNK1CDC25BCA12CA9
SCHEMBL3046656 0.81 CDC7 (0.43) MKNK2MKNK1CDC7MAPKAPK2CSNK1A1
SCHEMBL29937493 0.81 CDC7 (0.43) MKNK2MKNK1CDC7MAPKAPK2CSNK1A1
SCHEMBL5422250 0.71 MKNK2 (0.36) MKNK2MKNK1CDC25BCDC7MAPKAPK2
SCHEMBL19553234 0.71 DAPK3 (0.47) MKNK2MKNK1CDC25BCDC7MAPKAPK2
SCHEMBL30021651 0.71 MKNK2 (0.36) MKNK2MKNK1CDC25BCDC7MAPKAPK2
SCHEMBL30978396 0.70 — —
SCHEMBL2223651 0.69 CA12 (0.50) CDC25BCA12CA9PIM1CSNK1A1
SCHEMBL25323349 0.69 PARP16 (0.38) MKNK2MKNK1CA12CA9CDC7
SCHEMBL31310037 0.69 PRF1 (0.41) MKNK2CA12CA9CDC7PARP16

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4486454-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-01-08 — — EP disclosed
US-20230312474-A1 PHENOL DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-10-05 — — US disclosed
US-20230312474-A1 PHENOL DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-10-05 — — US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
WO-2023156648-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-24 — — WO disclosed
EP-4206184-A1 PHENOL DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-07-05 — — EP disclosed
CN-110872297-B Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application 上海再极医药科技有限公司 2023-02-14 — — CN disclosed
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 — — US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 — — US disclosed
EP-3707151-B1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICALS CO (JP) 2022-01-05 — — EP disclosed
US-20150336964-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-26 — — US disclosed
US-9181255-B2 Fused heteroaromatic pyrrolidinones as SYK inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-9108970-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-08-18 — — US disclosed
EP-2902392-A1 Fused heteroaromatic pyrrolidinones as syk inhibitors Takeda Pharmaceutical Company Limited (JP) 2015-08-05 — — EP disclosed
EP-2516434-B1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-05-27 — — EP disclosed
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2013-09-19 — — US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 — — US disclosed
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TREMBLEY MARCELLA 2009-04-02 — — US disclosed
EP-1890673-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSMIP Assets B.V. (NL) 2008-02-27 — — EP disclosed
WO-2006133876-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSM IP ASSETS B.V. (NL) 2006-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS SYK, BTK, LYN MKNK2 990/4885MKNK1 1012/4885CDC25B 869/4885
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TYMP, TYMS, UNG MKNK2 3291/4885MKNK1 3181/4885CDC25B 261/4885
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN MKNK2 1731/4885MKNK1 1728/4885CDC25B 1102/4885
US-20230312474-A1 PHENOL DERIVATIVE TYR, NCOR1, BET1 MKNK2 3549/4885MKNK1 3378/4885CDC25B 2642/4885
US-20150336964-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN MKNK2 1731/4885MKNK1 1728/4885CDC25B 1102/4885
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL MKNK2 3398/4885MKNK1 3858/4885CDC25B 3581/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 MKNK2 3034/4885MKNK1 3585/4885CDC25B 3370/4885
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN MKNK2 1731/4885MKNK1 1728/4885CDC25B 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.